A NEW ALTERNATIVE IN MIGRAINE TREATMENT: ELETRIPTAN HYDROBROMIDE BUCCAL ORGANOGELS
Abstract
Migraine is a disorder characterized by severe, intermittent throbbing pain in the head, often accompanied by sensitivity to light and sound, as well as nausea and vomiting. Eletriptan hydrobromide (EHB) is a highly selective serotonin 5-HT1B/1D receptor agonist administered orally in the acute treatment of moderate or severe migraine attacks. In migraine patients, pain-induced vomiting and nausea may complicate medication intake. Inhibition of critical gastrointestinal motility and delayed gastric emptying time during a migraine attack is also a major problem. Taking into consideration all these data, the importance of unconventional dosage forms in migraine treatment emerges. The fact is that buccal formulations are important in terms of rapid effect, easy use in patients with swallowing difficulties, and ease of use in patients with nausea/vomiting complaints, and in cases requiring drug intake without water.
Keywords:
References
Jones, D. S., Bruschi, M. L., de Freitas, O., Gremião, M. P. D., Lara, E. H. G., Andrews, G. P. 2009. "Rheological, mechanical and mucoadhesive properties of thermoresponsive, bioadhesive binary mixtures composed of poloxamer 407 and carbopol 974P designed as platforms for implantable drug delivery systems for use in the oral cavity". International Journal of Pharmaceutics, 372(1–2), 49–58.
Karavana, S. Y., Rençber, S., Ay, Z., Balo, E. 2012. "A New In-Situ Gel Formulation of Itraconazole for Vaginal Administration", 2012(October), 417–426.
Diener, H. C., Pfaffenrath, V., Schnitker, J., Friede, M., Henneicke-Von Zepelin, H. H. 2005. "Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention - A randomized, double-blind, multicentre, placebo-controlled study". Cephalalgia, 25(11), 1031–1041.
Readership
Published
Issue
Section
How to Cite
